Roche struck a cancer drug licensing deal with China's Hansoh that could exceed $15 billion

What happened: Roche struck a cancer drug licensing deal with China's Hansoh that could exceed $15 billion. Hansoh keeps rights to the programs in mainland China, Hong Kong, Macau and Taiwan. Key numbers: Upfront payment of $400 million; deal value could exceed $15 billion. Why it matters: The arrangement gives Roche access to Hansoh's cancer programs outside Greater China while Hansoh retains regional rights and receives upfront cash.

Roche struck a cancer drug licensing deal with China's Hansoh that could exceed $15 billion. Hansoh keeps rights to the programs in mainland China, Hong Kong, Macau and Taiwan.

The arrangement gives Roche access to Hansoh's cancer programs outside Greater China while Hansoh retains regional rights and receives upfront cash.